Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Are peptides legal in North Carolina?

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer

Yes. A North Carolina resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a North Carolina-licensed prescriber, including by telemedicine; North Carolina has no general telehealth practice statute, and the North Carolina Medical Board's telemedicine position statement allows a licensee-patient relationship to be established by synchronous or asynchronous telemedicine without an in-person visit when the standard of care is met, but it does not accept prescribing based solely on a static online questionnaire. A compounded peptide is available when it is eligible under federal 503A rules and dispensed by a pharmacy permitted by the North Carolina Board of Pharmacy; out-of-state pharmacies must register annually under G.S. 90-85.21A. The Board's pharmacy FAQ says compounding copies of approved tirzepatide products is no longer allowed and that FDA's grace period for 503A copies of semaglutide ended April 22, 2025.

Regulatory: Telehealth allowedRegulatory: Async allowedRegulatory: Compounded GLP-1 limitedVerified: Verified Oct 28, 2026
Compounding rules
Follows the federal 503A framework
Telehealth prescribing
Allowed, asynchronous allowed; a questionnaire alone is not enough
Compounded GLP-1
Limited

Can a North Carolina resident get peptides by telehealth?

North Carolina regulates telemedicine prescribing mainly through North Carolina Medical Board Position Statement 5.1.4 (Telemedicine, amended March 2024) rather than a practice statute. The Board says a licensee-patient relationship may be established through either synchronous or asynchronous telemedicine technologies without a prior in-person meeting, so long as the standard of care is met, and that licensees may use their judgment to prescribe as part of a telemedicine encounter. It also says diagnosis or prescribing based solely on static online questionnaires is not acceptable, and that licensees who use questionnaires should be able to ask follow-up questions. Position Statement 4.1.1 adds that prescribing to someone the licensee has never met based solely on answers to a set of questions is unprofessional. Telemedicine-only care may be unsuitable in some cases, including the treatment of pain. The prescriber must hold a North Carolina license. None of the peptides in this database are controlled substances. This record classifies asynchronous prescribing as allowed because the Board's position statement in force today expressly permits asynchronous technology to establish the relationship and permits prescribing, while barring questionnaire-only prescribing. A position statement is board policy, not a rule. [2] [3]

How does the North Carolina pharmacy board treat compounding?

Compounding regulator for North Carolina
BoardNorth Carolina Board of Pharmacy
Eligible substancesFollows the federal 503A framework

The Board of Pharmacy issues pharmacy permits under the North Carolina Pharmacy Practice Act (G.S. Chapter 90, Article 4A) and adopts rules in 21 NCAC 46, including the compounding rule in Section .2800. Under G.S. 90-85.21A, any pharmacy outside North Carolina that ships, mails, or delivers dispensed legend drugs into the state must register with the Board every year, and the Board may deny registration to a pharmacy disciplined in its home state for compounding or dispensing violations that threaten public health. The Board's July 2023 newsletter (Vol. 45, No. 1, Item 2465, "Statement Concerning Semaglutide Compounding") announced a Board staff guidance document on when federal law permits compounding a copy of a commercially available drug and how that applies to semaglutide; the Board's general pharmacy FAQ says the statement was updated after FDA's April 2023 clarification of semaglutide's shortage status, but the linked statement itself could not be retrieved from the Board's site when this record was checked, so its specific terms are not summarized here. The same FAQ now says FDA found semaglutide injection shortages resolved and would not act against state-licensed 503A pharmacies only until April 22, 2025, and that compounding copies of approved tirzepatide products is no longer allowed. North Carolina has no state bulks list; peptide eligibility follows the federal 503A framework. [1] [4] [5] [6] [7] [9]

Can you get compounded GLP-1s in North Carolina?

Regulatory: Compounded GLP-1 limited

Any out-of-state pharmacy shipping compounded GLP-1s in must hold an annual G.S. 90-85.21A registration. [4] [12]

Prices by channel: semaglutide cost, tirzepatide cost.

Approvals, shortage history, and prices for every GLP-1 we track are on the GLP-1 hub.

What is the legal access path in North Carolina?

Access options

We may earn a commission from these links.

Prices are the partner's own and are not verified by PeptideAgent. You answer health questions after checkout, and the partner's clinician decides whether to prescribe.

Unsponsored access paths are checked against public regulatory records. Sponsored offers are the partner's and are labeled. Products labeled research use only are never listed.

Find a provider in North Carolina

What you'll actually find in North Carolina, and how to check

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [16] [17] [18]

No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [19]

What North Carolina has done

PeptideAgent has not found a board or legislative action on peptides in North Carolina.

Other states have acted:

  • On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [21] Mississippi law
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [22] [23] Louisiana law

Checking the prescriber

Telehealth prescribing of non-controlled peptides is permitted in North Carolina. A prescriber may prescribe without a live visit (asynchronous care) when it meets the standard of care. State law says an online questionnaire alone is not enough. [2] [3] The telehealth rule in full.

Checking the pharmacy

Look the pharmacy up yourself before you pay, including an out-of-state mail-order pharmacy. The pharmacy regulator is the North Carolina Board of Pharmacy; its license search: FDA BeSafeRx: state board of pharmacy license lookups. [20]

If you're going ahead anyway

These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [19]

They do not change a peptide's legal status either. That depends on the peptide: for a withdrawn nomination such as BPC-157 or TB-500, a 503A pharmacy has no federal basis to compound it from bulk, with or without a prescription, while a few Category 1 substances, such as NAD+ and glutathione, are compounded under FDA's interim policy, with conditions. Each peptide page gives its status. [10] [24] [25]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [20] [26] [27]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [18] [27] [28]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [19] [29] [30] [31] [32] [33]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [19]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [20]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [18]
  • Pharmacy: Is this made for me on a prescription written in my name? [28]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [18] [27]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [18]

What is offered for a specific peptide, and what FDA found, is on each peptide page.

Is it legal to buy research peptides in North Carolina?

The North Carolina Food, Drug, and Cosmetic Act (G.S. 106-120 and following) prohibits selling adulterated or misbranded drugs, and the Pharmacy Practice Act restricts dispensing of legend drugs to permitted pharmacies. [5] [8] [13]

Peptide-specific notes for North Carolina

Peptide-specific notes for North Carolina
PeptideNote
SemaglutideAvailable branded by prescription, including by telemedicine from a North Carolina-licensed prescriber. Compounded semaglutide is limited to the federal patient specific exception since April 22, 2025, the date the North Carolina Board of Pharmacy's FAQ gives for the end of FDA's grace period for 503A pharmacies. [7] [12]

Frequently asked questions

Can I get a GLP-1 prescription in North Carolina through telemedicine?

Yes, from a North Carolina-licensed prescriber. The North Carolina Medical Board's telemedicine position says an evaluation need not be in person if the technology is sufficient to diagnose and treat under the standard of care, and semaglutide and tirzepatide are not controlled substances. [2]

Does North Carolina have a telehealth statute?

Not a general practice statute. North Carolina relies on the Medical Board's telemedicine position statement and general licensing law, so the standard of care governs what evaluation is needed before prescribing. The position statement allows synchronous or asynchronous telemedicine to establish the relationship, but it says prescribing based solely on static online questionnaires is not acceptable. [2]

Can an out-of-state pharmacy ship compounded peptides to me in North Carolina?

Only if it registers annually with the North Carolina Board of Pharmacy under G.S. 90-85.21A. The Board can refuse registration to pharmacies disciplined at home for compounding violations. [1] [4]

What has the North Carolina Board of Pharmacy said about compounded semaglutide?

In 2023 Board staff issued a guidance statement on if, when, and how semaglutide may be compounded, announced in the Board's July 2023 newsletter. The Board's current FAQ says FDA found semaglutide injection shortages resolved and stopped extending enforcement discretion to 503A pharmacies after April 22, 2025, and that compounding copies of approved tirzepatide products is no longer allowed. [6] [7]

Can a North Carolina pharmacy compound BPC-157?

Only under a draft federal policy, and only within strict limits. On October 28, 2026 HHS released a draft enforcement discretion policy saying it will not take enforcement action against a state-licensed pharmacy that compounds BPC-157 as a single-ingredient product by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. BPC-157 is still not FDA approved or on the 503A bulks list, the policy is not binding and HHS may revisit it, and blends such as Wolverine are not covered. FDA's drug center recommended against listing BPC-157; the advisory committee voted in favor (HHS policy, Appendix B). State law still applies: North Carolina has no state bulks list; peptide eligibility follows the federal 503A framework. [9] [10] [11] [14] [15]

Sources

Numbered citations above point to these primary sources: the state statute or rule, the pharmacy board, federal FDA guidance, and the FDA warning letters and studies behind what is offered.

  1. [1]North Carolina Board of Pharmacy
  2. [2]North Carolina Medical Board Position Statement 5.1.4, Telemedicine
  3. [3]North Carolina Medical Board Position Statement 4.1.1, Contact With Patients Before Prescribing
  4. [4]N.C. G.S. 90-85.21A, Pharmacies outside North Carolina (nonresident registration)
  5. [5]N.C. G.S. Chapter 90, Article 4A, North Carolina Pharmacy Practice Act
  6. [6]North Carolina Board of Pharmacy newsletter, July 2023 (semaglutide compounding)
  7. [7]North Carolina Board of Pharmacy: General pharmacy FAQs (compounding GLP-1s and semaglutide)
  8. [8]N.C. G.S. Chapter 106, Article 12, Food, Drug, and Cosmetic Act
  9. [9]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  10. [10]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, October 28). Are peptides legal in North Carolina?. https://peptideagent.ai/legal/north-carolina
HTML link
<a href="https://peptideagent.ai/legal/north-carolina">Are peptides legal in North Carolina?</a>, PeptideAgent, updated October 28, 2026.